14 stories found
Kailera Therapeutics has achieved a record-breaking initial public offering in the obesity treatment sector, making it a significant development that major pharmaceutical companies cannot afford to overlook.
Kailera's shares experienced a decline after the release of late-stage trial data for its oral GLP-1 candidate. The specific details of the trial data and the extent of the stock drop were not immediately clear.
Kailera Therapeutics' initial public offering was priced at $16 per share, with indications suggesting the stock will open at $24.
Biotech company Kailera made a strong debut on Nasdaq, raising $625 million in one of the largest biotech IPOs ever. Its stock soared over 60% on its first day of trading, driven by its involvement in the weight-loss drug market.
The US House of Representatives has passed a temporary bill to fund the Department of Homeland Security, addressing the ongoing shutdown and travel chaos at airports, though the shutdown is expected to continue for several weeks.
Kailera Therapeutics, Inc. has released its second-quarter financial results. The report provides an overview of the company's performance during the quarter.
Reports indicate that BlackRock is considering a multibillion-dollar investment in SpaceX's potential initial public offering. This news comes amidst ongoing speculation about when the Elon Musk-led company might go public.
The biotech sector is experiencing a resurgence in initial public offerings, with companies like Kailera and Alamar leading the way, indicating renewed investor demand.
GLP-1 developer Kailera has made history by raising $625 million in a record-breaking initial public offering, with shares priced at $16 each. This significant IPO marks a major milestone for the company in the pharmaceutical sector.
Kailera Therapeutics has officially filed for an Initial Public Offering (IPO) in the United States, seeking to list its shares on the stock market.
Figure Tech (FIGR) and Kailera Therapeutics (KLRA) are being highlighted as promising IPO stocks with substantial upside potential. These companies are considered strong investment opportunities.
An insider at Kailera Therapeutics (KLRA) has acquired an additional 500,000 shares of the company's stock, representing an investment of $8.0 million.
Kailera Therapeutics, a company focused on obesity treatments, saw its stock price surge by 63% following its $625 million initial public offering.
Kailera, a pharmaceutical company specializing in obesity drugs, is reportedly planning an Initial Public Offering (IPO).